{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:36:43Z","timestamp":1790339803541,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.diagmicrobio.2015.10.008","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T23:33:22Z","timestamp":1445556802000},"page":"266-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae"],"prefix":"10.1016","volume":"85","author":[{"given":"Dmitriy M.","family":"Martirosov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0005","series-title":"Poster presented at 3rd Annual IDWeek, October 8-12, 2014; Philadelphia, PA","article-title":"253. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii from New York City [abstract]","author":"Abdallah","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0010","series-title":"Actavis Receives U.S. FDA Approval for AVYCAZ\u2122 (CEFTAZIDIMEAVIBACTAM) [press release]","author":"Actavis","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae","volume":"39","author":"Aktas","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0025","series-title":"Poster presented at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013; Denver, CO","article-title":"E-1163. Impact of MK-7655 on imipenem MICs of a large collection of Enterobacteriaceae and pseudomonas aeruginosa isolates [abstract]","author":"Badal","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0030","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","article-title":"Eravacycline for the treatment of intra-abdominal infections","volume":"23","author":"Bassetti","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb1111","series-title":"Gentamine [package insert]","author":"Baxter","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb3333","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2125.1999.00850.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"47","author":"Begg","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2015.10.008_bb5555","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/BF01643430","article-title":"Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity","volume":"18","author":"Bergan","year":"1990","journal-title":"Infection"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0035","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0040","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for beta-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0045","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1128\/AAC.01707-08","article-title":"Resistance plasmid families in Enterobacteriaceae","volume":"53","author":"Carattoli","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0050","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1128\/AAC.00624-11","article-title":"Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects","volume":"55","author":"Cass","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0055","series-title":"Poster presented at 3rd Annual IDWeek, October 8-12, 2014; Philadelphia, PA","article-title":"257. In vitro activity of meropenem\/RPX7009, a carbapenem\/\u03b2-lactamase inhibitor combination tested against contemporary populations of Enterobacteriaceae and KPC-producing strains [abstract]","author":"Castanheira","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0060","series-title":"Antibiotic resistant threats in the United States","author":"CDC","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0065","author":"Cerexa Inc.","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0070","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb7777","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1128\/JCM.02494-07","article-title":"Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective","volume":"46","author":"Curcio","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb1212","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/cis286","article-title":"High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study","volume":"54","author":"Dalfino","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb1515","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0075","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0080","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb2121","unstructured":"Forest Pharmaceuticals Inc. Monurol [package insert]. Saint Louis, Missouri: Forest Pharmaceuticals, Inc; 2007."},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb2323","unstructured":"Forest Pharmaceuticals Inc. Avycaz [package insert]. Cincinnati, Ohio: Forest Pharmaceuticals, Inc; 2015."},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1179\/1973947812Y.0000000015","article-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece","volume":"24","author":"Galani","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0090","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1128\/AAC.03564-14","article-title":"Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections","volume":"58","author":"Gallagher","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2307\/30146962","article-title":"Resistance to imipenem among selected gram-negative bacilli in the United States","volume":"13","author":"Gaynes","year":"1992","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0100","series-title":"Poster presented at 3rd Annual IDWeek, October 8-12, 2014; Philadelphia, PA","article-title":"401. A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 alone, meropenem alone, and both in combination (carbavance) tid for 7days in healthy adult subjects [abstract]","author":"Griffith","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0110","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/AAC.01748-12","article-title":"KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy","volume":"57","author":"Hagihara","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0115","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciu1173","article-title":"Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae in long-term acute-care hospitals","volume":"60","author":"Hayden","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0120","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","article-title":"NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007","volume":"29","author":"Hidron","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb5656","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.107.015735","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects","volume":"35","author":"Hoffmann","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0125","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1128\/AAC.02411-12","article-title":"Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems","volume":"57","author":"Hong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/JB.164.1.223-229.1985","article-title":"Cloning and sequencing of the metallothioprotein beta-lactamase II gene of Bacillus cereus 569\/H in Escherichia coli","volume":"164","author":"Hussain","year":"1985","journal-title":"J Bacteriol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb6767","unstructured":"Jumes P, Rizk ML, Gutierrez M, Li X, Stoch SA, Wagner JA, et al. A phase I study evaluating the single-dose safety, tolerability, and pharmacokinetics of an intravenous beta-lactamase inhibitor in healthy elderly male, elderly female, and young female volunteers [abstract]. Poster presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9\u201312, 2012; San Francisco, CA; 2012."},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0140","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/AAC.43.7.1584","article-title":"Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate","volume":"43","author":"Lauretti","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0145","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1128\/AAC.00299-07","article-title":"Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital","volume":"51","author":"Leavitt","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-0711-11-32","article-title":"Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports","volume":"11","author":"Lee","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0160","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.45.10.2831-2837.2001","article-title":"Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0165","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0170","series-title":"Poster presented at The Society for Healthcare Epidemiology of America Spring 2015, May 14-17, 2015; Orlando, FL","article-title":"Prevalence of invasive gram-negative infections due to carbapenem-resistant Enterobacteriaceae (CRE) among adult patients in US intensive care units (ICUs) [abstract]","author":"Lodise","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jinf.2009.01.010","article-title":"Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece)","volume":"58","author":"Maltezou","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1086\/666642","article-title":"Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship","volume":"33","author":"Marchaim","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1086\/669087","article-title":"Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County","volume":"34","author":"Marquez","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0190","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/INF.0b013e31823c0e47","article-title":"Review of carbapenemases and AmpC-beta lactamases","volume":"30","author":"Marsik","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb9797","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0195","series-title":"Merck's investigational beta-lactamase inhibitor relebactam (MK-7655) granted qualified infectious disease product (QIDP) and fast track designations by FDA [press release]","author":"Merck & Co Inc.","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0200","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1469-0691.2011.03572.x","article-title":"Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals","volume":"17","author":"Mezzatesta","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb1678","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0205","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/AAC.47.1.395-397.2003","article-title":"Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-beta-lactamase VIM-1","volume":"47","author":"Miriagou","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb3121","unstructured":"Monarch Pharmaceuticals. 2006. Coly-Mycin [package insert]. Bristol, TN: Monarch Pharmaceuticals, Inc."},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb3971","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0210","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2014.12.004","article-title":"Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","author":"Ni","year":"2015","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0220","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0225","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jac\/dkr156","article-title":"Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae","volume":"66","author":"Patel","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0230","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1099\/jmm.0.2008\/002774-0","article-title":"Emergence of carbapenem-resistant Escherichia coli producing CMY-2-type AmpC beta-lactamase in Brazil","volume":"57","author":"Pavez","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0235","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/jac\/dkq191","article-title":"Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination","volume":"65","author":"Perez","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0240","series-title":"Poster presented at 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 10-13, 2013; Denver, CO","article-title":"E-1168b\u2014plazomicin is potent alone and in combination with other broad-spectrum agents, with no antagonism, against KPC-producing K. pneumoniae [abstract]","author":"Pillar","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.48.1.15-22.2004","article-title":"Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae","volume":"48","author":"Poirel","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0250","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/jac\/dkp207","article-title":"Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece","volume":"64","author":"Pournaras","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb3232","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/jac\/33.4.823","article-title":"Once-daily gentamicin versus once-daily netilmicin in patients with serious infections\u2014a randomized clinical trial","volume":"33","author":"Prins","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0255","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/CMR.00033-13","article-title":"Investigational antimicrobial agents of 2013","volume":"26","author":"Pucci","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0260","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/AAC.02813-13","article-title":"High incidence and endemic spread of NDM-1-positive Enterobacteriaceae in Henan Province, China","volume":"58","author":"Qin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0265","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0270","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/QCO.0000000000000109","article-title":"Options for treating carbapenem-resistant Enterobacteriaceae","volume":"27","author":"Rafailidis","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0275","article-title":"A phase 3, multi-center, randomized, double-blind, double-dummy study to evaluate the efficacy, safety, and tolerability of carbavance (meropenem\/RPX7009) compared to piperacillin\/tazobactam in the treatment of cUTIs, including AP, in adults","volume":"vol. NCT02166476","author":"Rempex Pharmaceuticals","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0280","article-title":"A phase 3, multi-center, randomized, open-label study of carbavance (meropenem\/RPX7009) versus best available therapy in subjects with selected serious infections due to carbapenem-resistant Enterobacteriaceae","volume":"vol. NCT02168946","author":"Rempex Pharmaceuticals","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0285","series-title":"Poster presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012; San Francisco, CA","article-title":"L2-2118a. Plazomicin safety and efficacy in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) [abstract]","author":"Riddle","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb9595","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb8585","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jac\/dkp230","article-title":"High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection","volume":"64","author":"Schintler","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0290","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/cid\/cir025","article-title":"Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention","volume":"52","author":"Schwaber","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0300","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0305","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0310","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/AAC.00783-09","article-title":"Dispersal of carbapenemase blaVIM-1 gene associated with different Tn402 variants, mercury transposons, and conjugative plasmids in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"54","author":"Tato","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/nyas.12537","article-title":"Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management","volume":"1323","author":"Temkin","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0320","series-title":"Tetraphase announces positive top-line results from phase 3 IGNITE 1 clinical trial of eravacycline in complicated intra-abdominal infections [press release]","author":"Tetraphase Pharmaceuticals Inc.","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0325","series-title":"Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cUTI [press release]","author":"Tetraphase Pharmaceuticals Inc.","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0330","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1469-0691.12697","article-title":"Treating infections caused by carbapenemase-producing Enterobacteriaceae","volume":"20","author":"Tzouvelekis","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0335","series-title":"NDA 206494 Ceftazidime-Avibactam","author":"US Food and Drug Administration","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0340","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0345","doi-asserted-by":"crossref","DOI":"10.2807\/ese.13.04.08023-en","article-title":"High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece\u2014a review of the current evidence","volume":"13","author":"Vatopoulos","year":"2008","journal-title":"Euro Surveill"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0350","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/jac\/dki482","article-title":"OXA-type carbapenemases","volume":"57","author":"Walther-Rasmussen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0355","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijantimicag.2013.02.015","article-title":"Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae","volume":"41","author":"Wiskirchen","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0360","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.48.12.4793-4799.2004","article-title":"Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center","volume":"48","author":"Woodford","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb2991","unstructured":"Wyeth Pharmaceuticals Inc. 2010. Tygacil [package insert]. Philadelphia, Pennsylvania: Wyeth Pahrmaceutials Inc."},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb2921","unstructured":"Xellia Pharmaceuticals. 2015. Polymyxin B for Injection [package insert]. Grayslake, IL: Xellia Pharmaceuticals, Inc."},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb3365","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","article-title":"Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae","volume":"45","author":"Yigit","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0370","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00774-09","article-title":"Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India","volume":"53","author":"Yong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0380","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"10","author":"Zhanel","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2015.10.008_bb0375","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/beta-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315003624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889315003624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T22:50:35Z","timestamp":1653346235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889315003624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0732889315003624"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.10.008","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}